Ruy Carlos Ruver Beck

Prof. Dr. Ruy Carlos Ruver Beck

Faculty of Pharmacy. Universidade Federal do Rio Grande do Sul, 90040-060 Porto Alegre-RS, Brazil
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
Ruy Carlos Ruver BeckRuy Carlos Ruver Beck
Ruy Carlos Ruver Beck
PCP.S. Chaves
P.S. Chaves
AGAlvaro Goyanes
Alvaro Goyanes
BVB. Vukosavljevic
B. Vukosavljevic
Asma BuanzAsma Buanz
Asma Buanz
Simon GaisfordSimon Gaisford
Simon Gaisford

1 September 2014 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
KCK. Coradini
K. Coradini
FLF.O. Lima
F.O. Lima
COC.M. Oliveira
C.M. Oliveira
PCP.S. Chaves
P.S. Chaves
MAM.L. Athayde
M.L. Athayde
Ruy Carlos Ruver BeckRuy Carlos Ruver Beck
Ruy Carlos Ruver Beck

1 February 2013 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
Alfeu Zanotto-FilhoAlfeu Zanotto-Filho
Alfeu Zanotto-Filho
KCKarine Coradini
Karine Coradini
EBElizandra Braganhol
Elizandra Braganhol
RSRafael Schröder
Rafael Schröder
COCláudia Melo de Oliveira
Cláudia Melo de Oliveira
JMJosé Cláudio Fonseca Moreira
José Cláudio Fonseca Moreira

30 January 2015 in WIREs Nanomedicine and Nanobiotechnology
Verified
Journal Article
Closed access
PDF file
LUIZA ABRAHAO FRANKLUIZA ABRAHAO FRANK
LUIZA ABRAHAO FRANK
RCRenata V. Contri
Renata V. Contri
Ruy Carlos Ruver BeckRuy Carlos Ruver Beck
Ruy Carlos Ruver Beck
APAdriana Pohlmann
Adriana Pohlmann
SGSilvia Guterres
Silvia Guterres

8 September 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Juliana dos SantosJuliana dos Santos
Juliana dos Santos
GSGuilherme Silveira da Silva
Guilherme Silveira da Silva
MVMaiara Callegaro Velho
Maiara Callegaro Velho
Ruy Carlos Ruver BeckRuy Carlos Ruver Beck
Ruy Carlos Ruver Beck
Eudragit® polymers are polymethacrylates highly used in pharmaceutics for the development of modified drug delivery systems. They are widely known due to their versatility with regards to chemical composition, solubility, and swelling properties. Moreover, Eudragit polymers are thermoplastic, and their use has been boosted in some production processes, such as hot melt extrusion (HME) and fused deposition modelling 3D printing, among other 3D printing techniques. Therefore, this review covers the studies using Eudragit polymers in the development of drug delivery systems produced by HME and 3D printing techniques over the last 10 years. Eudragit E has been the most used among them, mostly to formulate immediate release systems or as a taste-masker agent. On the other hand, Eudragit RS and Eudragit L100-55 have mainly been used to produce controlled and delayed release systems, respectively. The use of Eudragit polymers in these processes has frequently been devoted to producing solid dispersions and/or to prepare filaments to be 3D printed in different dosage forms. In this review, we highlight the countless possibilities offered by Eudragit polymers in HME and 3D printing, whether alone or in blends, discussing their prominence in the development of innovative modified drug release systems.

11 February 2021 in Advanced Functional Materials
Verified
Journal Article
Closed access
PDF file
Juliana dos SantosJuliana dos Santos
Juliana dos Santos
RORafaela S. de Oliveira
Rafaela S. de Oliveira
TOThayse V. de Oliveira
Thayse V. de Oliveira
MVMaiara C. Velho
Maiara C. Velho
MKMartina V. Konrad
Martina V. Konrad
Ruy Carlos Ruver BeckRuy Carlos Ruver Beck
Ruy Carlos Ruver Beck